Altimmune Inc (NASDAQ:ALT) — Market Cap & Net Worth
Market Cap & Net Worth: Altimmune Inc (ALT)
Altimmune Inc (NASDAQ:ALT) has a market capitalization of $413.26 Million ($413.26 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13297 globally and #3236 in its home market, demonstrating a 0.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Altimmune Inc's stock price $3.30 by its total outstanding shares 125231517 (125.23 Million). Also see total assets of Altimmune Inc for a full breakdown of the balance sheet.
Altimmune Inc Market Cap History: 2015 to 2026
Altimmune Inc's market capitalization history from 2015 to 2026. Data shows change from $71.17 Billion to $413.26 Million (-36.80% CAGR). Also see ALT cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Altimmune Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.02% | #361 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #1301 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.02% | #197 of 263 |
Weight: Altimmune Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Altimmune Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Altimmune Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Altimmune Inc stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
11026.48x
Altimmune Inc's market cap is 11026.48 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $121.74 Billion | $5.23 Million | $193.85 Million | 23276.72x | 628.01x |
| 2017 | $7.48 Billion | $41.50K | -$46.43 Million | 180139.30x | N/A |
| 2018 | $257.98 Million | $10.33 Million | -$39.17 Million | 24.97x | N/A |
| 2019 | $236.69 Million | $5.80 Million | -$20.52 Million | 40.80x | N/A |
| 2020 | $1.41 Billion | $8.19 Million | -$49.04 Million | 172.58x | N/A |
| 2021 | $1.15 Billion | $4.41 Million | -$97.09 Million | 260.12x | N/A |
| 2022 | $2.06 Billion | $-68.00K | -$84.71 Million | -30294.98x | N/A |
| 2023 | $1.41 Billion | $426.00K | -$88.45 Million | 3307.17x | N/A |
| 2024 | $902.92 Million | $20.00K | -$95.06 Million | 45145.96x | N/A |
| 2025 | $452.09 Million | $41.00K | -$88.09 Million | 11026.48x | N/A |
Competitor Companies of ALT by Market Capitalization
Companies near Altimmune Inc in the global market cap rankings as of September 17, 2026. Review ALT goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Altimmune Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Altimmune Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Altimmune Inc's market cap moved from $71.17 Billion to $ 413.26 Million, with a yearly change of -36.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $413.26 Million | -8.59% |
| 2025 | $452.09 Million | -49.93% |
| 2024 | $902.92 Million | -35.91% |
| 2023 | $1.41 Billion | -31.61% |
| 2022 | $2.06 Billion | +79.59% |
| 2021 | $1.15 Billion | -18.79% |
| 2020 | $1.41 Billion | +496.83% |
| 2019 | $236.69 Million | -8.25% |
| 2018 | $257.98 Million | -96.55% |
| 2017 | $7.48 Billion | -93.86% |
| 2016 | $121.74 Billion | +71.05% |
| 2015 | $71.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Altimmune Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $413.26 Million USD |
| MoneyControl | $413.26 Million USD |
| MarketWatch | $413.26 Million USD |
| marketcap.company | $413.26 Million USD |
| Reuters | $413.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.